Qiagen (NYSE:QGEN) Shares Bought by Tidal Investments LLC

Tidal Investments LLC boosted its holdings in shares of Qiagen (NYSE:QGEN - Free Report) by 72.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,559 shares of the company's stock after purchasing an additional 7,815 shares during the quarter. Tidal Investments LLC's holdings in Qiagen were worth $826,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of QGEN. Brown Brothers Harriman & Co. bought a new position in Qiagen during the fourth quarter valued at $37,000. Geneos Wealth Management Inc. increased its position in Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after acquiring an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after acquiring an additional 526 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after acquiring an additional 835 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Qiagen by 770.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of research analyst reports. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group cut their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Robert W. Baird upped their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Finally, Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Qiagen presently has an average rating of "Hold" and a consensus target price of $48.42.

Qiagen Stock Up 1.2%

Qiagen stock traded up $0.51 during midday trading on Wednesday, hitting $44.36. 1,415,041 shares of the company's stock were exchanged, compared to its average volume of 1,157,441. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a 12 month low of $37.63 and a 12 month high of $49.30. The firm has a 50-day moving average of $41.49 and a two-hundred day moving average of $41.84. The company has a market cap of $9.86 billion, a PE ratio of 123.52, a P/E/G ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The business had revenue of $483.46 million for the quarter, compared to analysts' expectations of $465.66 million. During the same period last year, the business earned $0.44 EPS. The company's revenue was up 5.2% compared to the same quarter last year. As a group, analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.